This monthly feature will help readers keep current on new drugs, new indications, dosage forms, and safety-related changes in labeling or use. Efforts have been made to ensure the accuracy of this information; however, if there are any questions, please let me know at danial.baker@wsu.edu.
. New drugs approved by the US Food and Drug Administration: May 16, 2015 through July 12, 2015 Lumacaftor/ivacaftor -Orkambi (Vertex Pharmaceuticals)
Comparative agents: Ivacaftor
Indication: Treatment of cystic fibrosis in patients age 12 years and older who are homozygous for the F508del mutation in the transmembrane conductance regulator (CFTR) gene. If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of the F508del mutation on both alleles of the CFTR gene.
Mechanism of action:
Transmembrane conductance regulator potentiator Treatment of hypoactive sexual desire disorder in premenopausal women; committee vote was 18 to 6 for approval.
Mepolizumab
(GlaxoSmithKline) Treatment of severe asthma in adults (14 to 0 in favor of approval); committee did not support its use in adolescents (10 to 4 against).
Necitumumab (Eli Lilly)
Combination with gemcitabine and cisplatin for first-line treatment of patients with locally advanced or metastatic squamous non-small-cell lung cancer; community supported its use but no formal vote was taken at the meeting. Mepolizumab (GlaxoSmithKline) Add-on maintenance treatment in patients 12 years and older with severe eosinophilic asthma identified by blood eosinophils greater than or equal to 150 cells/microliter at initiation of treatment or blood eosinophils greater than or equal to 300 cells/microliter in the past 12 months [July 2015]
Current FDA-Related Drug Information • aminotransferase elevations are accompanied by total bilirubin elevation greater than 2 times the upper limit of normal. • aminotransferase elevations are greater than 8 times the upper limit of normal. • aminotransferase elevations are greater than 5 times the upper limit of normal and persist beyond 2 weeks. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm368240.htm
(continued)
Current FDA-Related Drug Information Gilenya was similar to placebo. However, bronchitis, herpes zoster, influenza, sinusitis, and pneumonia were more common in Gilenya-treated patients. Serious infections occurred at a rate of 2.3% in the Gilenya group versus 1.6% in the placebo group.
(CONT.) (continued) Current FDA-Related Drug Information Current FDA-Related Drug Information 
CONTRAINDICATIONS
• Known anaphylactic reaction or angioedema ADVERSE REACTIONS The following adverse reactions have been reported in women taking Provera tablets, without concomitant estrogens treatment:
• Hypersensitivity reactions (eg, anaphylaxis and anaphylactoid reactions, angioedema), rash (allergic) with and without pruritus, change in weight (increase or decrease), pyrexia, edema/fluid retention, fatigue, decreased glucose tolerance The following adverse reactions have been reported with estrogen plus progestin therapy:
• (CONT.) (continued) Current FDA-Related Drug Information Class warning regarding cardiovascular risk: Long-term clinical safety trials have not been conducted to assess the cardiovascular outcomes of testosterone replacement therapy in men. To date, epidemiologic studies and randomized controlled trials have been inconclusive for determining the risk of major adverse cardiovascular events (MACE), such as non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death, with the use of testosterone compared to non-use. Some studies, but not all, have reported an increased risk of MACE in association with use of testosterone replacement therapy in men. Patients should be informed of this possible risk when deciding whether to use or to continue to use. 
